Evidence map›Paper›PMID 38311687›Full record

ArticleJapanese journal of ophthalmology2024

Injectable in situ cross-linking hyaluronan hydrogel for easier removal of posterior vitreous cortex in vitrectomy.

Toshio Hisatomi, Takashi Tachibana, Kenichiro Mori, Keijiro Ishikawa, Tatsuro Ishibashi, Koh-Hei Sonoda, Eiichi Uchio, Ippei Watanabe, Kiyoshi Suzuki, Masami Iida

Abstract read
PubMed Publisher
In one paragraph

Article in Japanese journal of ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Toshio HisatomiDepartment of Ophthalmology, Fukuoka University Chikushi Hospital, 1-1-1 Zokumyoin, Chikushino, Fukuoka, 818-8502, Japan. t.hisatomi.qk@fukuoka-u.ac.jp.ORCID http://orcid.org/0000-0003-2552-9595
Takashi TachibanaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Kenichiro MoriDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Keijiro IshikawaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Tatsuro IshibashiDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Koh-Hei SonodaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Eiichi UchioDepartment of Ophthalmology, Faculty of Medicine, Fukuoka University, 8-19-1, Nanakuma, Fukuoka Jonan-ku, Fukuoka, 814-080, Japan.
Ippei WatanabeCentral Research Laboratory, Seikagaku Corporation, 1253, Tateno 3-chome, Higashiyamato-shi, Tokyo, 207-0021, Japan.
Kiyoshi SuzukiCentral Research Laboratory, Seikagaku Corporation, 1253, Tateno 3-chome, Higashiyamato-shi, Tokyo, 207-0021, Japan.
Masami IidaCentral Research Laboratory, Seikagaku Corporation, 1253, Tateno 3-chome, Higashiyamato-shi, Tokyo, 207-0021, Japan.
Kyushu University · JPSeikagaku Corporation (Japan) · JPFukuoka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRemoving transparent vitreous tissues, such as a residual vitreous cortex (VC) or proliferative membrane, without damaging the retina is often problematic in vitrectomy. We examined the feasibility of an injectable in situ cross-linking hyaluronan hydrogel (XL-HA) for vitrectomy. STUDY

designExperiments using ex vivo and in vivo animal models.

methodsHA-dibenzocyclooctyne and HA-azidoethylamine solutions were mixed to form XL-HA, which then gradually formed a hydrogel. We tested the function of XL-HA in ex vivo porcine eyes. We then examined the performance of XL-HA in in vivo rabbit models of posterior vitreous detachment, posterior VC removal, and proliferative vitreoretinopathy.

resultsThe ex vivo study showed that XL-HA rapidly embedded triamcinolone acetonide, mimicking VC attached to the retina, and became hard enough to be pinched with tweezers within 3 minutes, allowing us to remove only the triamcinolone acetonide without impairing the internal limiting membrane. In the in vivo rabbit models, XL-HA injection improved posterior vitreous detachment, and the thin and fragile posterior VC or fibrous proliferative membrane was readily peeled off without any damage to the underlying retina as compared with untreated controls. A short-term intraocular biocompatibility test demonstrated that the intraocular pressure remained normal with XL-HA injected into the eye. In addition, transmission electron microscopy showed no obvious abnormalities in the cornea or in the inner and outer retina.

conclusionThe results indicate that XL-HA is a potential adjunctive device to help make vitrectomy safe, effective, and successful.

Indexed as

VitrectomyVitreous DetachmentAnimalsGlucocorticoidsHyaluronic AcidHydrogelsRabbitsSwineTriamcinolone AcetonideVitreous BodyGlucocorticoidsHyaluronic AcidHydrogelsTriamcinolone AcetonideAnimal modelCross-linking hyaluronan hydrogelPosterior vitreous cortexProliferative membraneVitrectomy

Identifiers

PMID38311687
OpenAlexW4391537192

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.